Technical Analysis for ENTO - Entero Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.12 | -8.95% | -0.11 |
ENTO closed down 8.95 percent on Monday, July 1, 2024, on 4.46 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -8.95% |
| Alert | Time |
|---|---|
| 5x Volume Pace | about 7 hours ago |
| 3x Volume Pace | about 8 hours ago |
| 2x Volume Pace | about 9 hours ago |
| Down 5% | about 9 hours ago |
| New 52 Week Low | about 9 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/14/2024
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmacy Medication Gastrointestinal Disease Gastrointestinal Tract Covid 19
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.998 |
| 52 Week Low | 0.9999 |
| Average Volume | 67,374 |
| 200-Day Moving Average | 4.68 |
| 50-Day Moving Average | 2.48 |
| 20-Day Moving Average | 2.02 |
| 10-Day Moving Average | 1.67 |
| Average True Range | 0.27 |
| RSI (14) | 20.00 |
| ADX | 45.18 |
| +DI | 5.44 |
| -DI | 33.70 |
| Chandelier Exit (Long, 3 ATRs) | 2.05 |
| Chandelier Exit (Short, 3 ATRs) | 1.81 |
| Upper Bollinger Bands | 2.93 |
| Lower Bollinger Band | 1.12 |
| Percent B (%b) | 0.0 |
| BandWidth | 89.68 |
| MACD Line | -0.38 |
| MACD Signal Line | -0.30 |
| MACD Histogram | -0.0774 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.45 | ||||
| Resistance 3 (R3) | 1.45 | 1.33 | 1.40 | ||
| Resistance 2 (R2) | 1.33 | 1.25 | 1.34 | 1.38 | |
| Resistance 1 (R1) | 1.23 | 1.20 | 1.17 | 1.23 | 1.36 |
| Pivot Point | 1.11 | 1.11 | 1.08 | 1.11 | 1.11 |
| Support 1 (S1) | 1.01 | 1.03 | 0.95 | 1.01 | 0.88 |
| Support 2 (S2) | 0.89 | 0.98 | 0.89 | 0.86 | |
| Support 3 (S3) | 0.79 | 0.89 | 0.84 | ||
| Support 4 (S4) | 0.79 |
